Gilead, Roche and Merck KGaA favor early-stage drug assets over full company buyouts
Per Stocktwits, large drugmakers bought early-stage drug candidates this week instead of whole biotech companies, led by Gilead, Roche and Merck KGaA deals.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to Stocktwits, large drugmakers this week leaned toward targeted asset purchases and licensing agreements for early-stage drugs instead of acquiring entire companies. Full takeovers, which dominated earlier in the year, took a back seat. The most capital flowed into inflammation, antibody-drug conjugates for cancer and next-generation T-cell engagers.
Gilead agreed to pay $1.275 billion in cash for an experimental oral inflammatory program from Shanghai-based PepStar Therapeutics, with closing expected in the fourth quarter. Roche gained exclusive global rights to Zymeworks' ZW209 in a deal worth up to $813 million, including $55 million upfront. Merck KGaA agreed to buy Silence Therapeutics for about $1.3 billion in cash, offering $20 per American Depositary Share.
why it matters
The shift matters for markets because pharma is choosing flexible licenses over costly takeovers, which lowers overpayment risk and keeps attention on smaller biotech firms holding promising assets. Individual deals are modest for the sector, so index-level effects are limited, though shares of the named companies may move on the announcements.
market impact
GILD, RHHBY, ZYME, SLN: deals reshape pipelines; Silence sees the largest direct effect from its buyout.
tags
instruments
sources
- Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This Week — Stocktwits, 24 October 2026 at 00:01 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗